Nkarta, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nkarta, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $603.00K.
- Nkarta, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.00K.
- Nkarta, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $1.00K.
- Nkarta, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $90.00K, a 328.57% increase year-over-year.
- Nkarta, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $668.00K, a 314.91% increase from fiscal 2023.
- Nkarta, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $161.00K, a 88.48% decline from fiscal 2022.
- Nkarta, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.40M, a 5.54% decline from fiscal 2021.
- Nkarta, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.48M, a 282.17% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $603.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $6.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $668.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $1.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $90.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $578.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $161.00K 10-K · filed 2025-03-26 | |
| 2023-06-30 | $21.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.40M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $953.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $334.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $79.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $1.48M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $318.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $256.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $756.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $387.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $36.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $285.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $1.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $3.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |